Alarcón T, Domingo D, Sánchez I, Sanz J C, Martínez M J, López-Brea M
Department of Microbiology, Hospital Universitario de la Princesa, Madrid, Spain.
Eur J Clin Microbiol Infect Dis. 1998 Apr;17(4):275-7. doi: 10.1007/BF01699986.
The aim of this study was to determine the in vitro activity of ranitidine, ebrotidine, bismuth citrate, omeprazole, and lansoprazole against 113 clinical isolates of Helicobacter pylori cultured from gastric biopsies. An agar dilution method using Mueller-Hinton agar plus 7%, horse blood, an inoculum of 10(6) cfu/spot, and incubation in a CO2 incubator for 2 to 5 days was used. The minimum inhibitory concentrations for 50 and 90% of the isolates tested, respectively, were as follows: ranitidine, 1024 and 1024 mg/l; ebrotidine, 64 and 256 mg/l; bismuth citrate, 1 and 4 mg/l; omeprazole, 16 and 16 mg/l; and lansoprazole, 1 and 1 mg/l. Ebrotidine was more active than ranitidine, and lansoprazole was the most active compound against the Helicobacter pylori isolates tested.
本研究的目的是测定雷尼替丁、依罗替丁、枸橼酸铋、奥美拉唑和兰索拉唑对从胃活检组织培养的113株幽门螺杆菌临床分离株的体外活性。采用琼脂稀释法,使用添加7%马血的穆勒-欣顿琼脂、每点接种10(6) cfu的菌悬液,并在二氧化碳培养箱中孵育2至5天。所测试的50%和90%分离株的最低抑菌浓度分别如下:雷尼替丁,1024和1024 mg/l;依罗替丁,64和256 mg/l;枸橼酸铋,1和4 mg/l;奥美拉唑,16和16 mg/l;兰索拉唑,1和1 mg/l。依罗替丁比雷尼替丁活性更强,兰索拉唑是所测试的幽门螺杆菌分离株中活性最强的化合物。